HPLC测定中药多成分总量溶度参数的理论及实验研究

Theoretical and experimental studies on apparent solubility parameters of multiple components for Chinese materia medica with HPLC fingerprint

目的:创立HPLC指纹图谱总量几何平均保留时间测定中药多成分表观溶度参数的理论与方法。方法:运用指纹图谱总量几何平均保留时间能表达HPLC指纹图谱特征峰的整体趋势特点,建立其与多成分表观溶度参数的内在函数式,用已知溶度参数的芦荟大黄素类成分进行实验证明,并测定左金方的表观溶度参数。HPLC条件:A lltech Apollo C18色谱柱(4.6 mm×250 mm,5μm);流动相乙腈-水,梯度洗脱;检测波长430 nm;柱温30℃。结果:建立了指纹图谱几何平均保留时间与总量表观溶度参数关联的数学表达式,用此法测得芦荟大黄素等混合物表观溶度参数为36.12 J1/2.cm-3/2,按峰面积比算得值为35.57 J1/2.cm-3/2,按摩尔分数算得值36.07 J1/2.cm-3/2。结论:HPLC指纹图谱总量几何平均保留时间法能同时测定多个成分及总量的表观溶度参数,这对研究中药的配伍溶解规律,单味中药剂改工艺研究奠定理论基础。

Objective： To establish the theories and methods to determine apparent solubility parameters of multiple components for the Chinese materia medica（CMM） with HPLC fingerprint.Method： The mathematical functional expresses to determine the apparent solubility parameters for multiple constituents were established according to total quantum geometrical average retention time（TQGART） for HPLC fingerprint that characterized the entirety tendencies for all-over chromatographic peaks,validated by the aloe-emodin′s solubility parameters which had been determined.The HPLC for the aloe-emodin′s solubility parameters were carried out with an Alltech Apollo C18 as column,Acetone：Water as mobile phase,gradient elution,flow rate as 1.0 mL·min-1,the detection wavelength as 430 nm and the temperature as 30 ℃.Result： The mathematical functional model between the TQGART of HPLC chromatographic fingerprint and the total quantum apparent solubility parameters was established and used to determine the aloe-emodin′s mixture solubility parameter as 36.12 J1/2·cm-3/2,nearly equal to 35.57,36.07 J1/2·cm-3/2 calculated by ration of peak area ratios and molecular fraction,respectively.Conclusion： The TQGART of HPLC fingerprint can be used to determine simultaneously the apparent or single intrinsic solubility parameters for total quantum or intrinsic solubility parameters for single in multiple constitute systems,by which theoretical and technologic platform to study the compatibility rule and dosage form reform of the single CMM will be established.